Schiff R - Search Results

1

Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance.

Zhou Y, Gerrard DL, Wang J, Li T, Yang Y, Fritz AJ, Rajendran M, Fu X, Stein G, Schiff R, Lin S, Frietze S, Jin VX. Zhou Y, et al. Among authors: schiff r. Nat Commun. 2019 Apr 3;10(1):1522. doi: 10.1038/s41467-019-09320-9. Nat Commun. 2019. PMID: 30944316 Free PMC article.

2

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Schiff R, Massarweh S, Shou J, Osborne CK. Schiff R, et al. Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S. Clin Cancer Res. 2003. PMID: 12538499 Review.

3

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.

Osborne CK, Schiff R. Osborne CK, et al. Among authors: schiff r. Breast. 2003 Dec;12(6):362-7. doi: 10.1016/s0960-9776(03)00137-1. Breast. 2003. PMID: 14659106 Review.

4

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Shou J, et al. Among authors: schiff r. J Natl Cancer Inst. 2004 Jun 16;96(12):926-35. doi: 10.1093/jnci/djh166. J Natl Cancer Inst. 2004. PMID: 15199112

5

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

Osborne CK, Shou J, Massarweh S, Schiff R. Osborne CK, et al. Among authors: schiff r. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s. Clin Cancer Res. 2005. PMID: 15701879 Review.

6

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Gutierrez MC, et al. Among authors: schiff r. J Clin Oncol. 2005 Apr 10;23(11):2469-76. doi: 10.1200/JCO.2005.01.172. Epub 2005 Mar 7. J Clin Oncol. 2005. PMID: 15753463

7

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Arpino G, et al. Among authors: schiff r. J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. doi: 10.1093/jnci/dji249. J Natl Cancer Inst. 2005. PMID: 16145046

8

Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.

Schiff R, Osborne CK. Schiff R, et al. Breast Cancer Res. 2005;7(5):205-11. doi: 10.1186/bcr1287. Epub 2005 Jul 20. Breast Cancer Res. 2005. PMID: 16168139 Free PMC article.

9

Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Cui X, et al. Among authors: schiff r. J Clin Oncol. 2005 Oct 20;23(30):7721-35. doi: 10.1200/JCO.2005.09.004. J Clin Oncol. 2005. PMID: 16234531 Review.

10

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.

Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV. Divisova J, et al. Among authors: schiff r. Breast Cancer Res Treat. 2006 Aug;98(3):315-27. doi: 10.1007/s10549-006-9168-1. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541323

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

378 results

Search Page

Filters